Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 5 Treatment with BMS-986165 (PO BID) protects from wasting and colitis in two SCID mouse models. Treatment with BMS-986165 (PO BID) protects from.

Published byPeter Fields Modified over 5 years ago

Similar presentations

Presentation on theme: "Fig. 5 Treatment with BMS-986165 (PO BID) protects from wasting and colitis in two SCID mouse models. Treatment with BMS-986165 (PO BID) protects from."— Presentation transcript:

1 Fig. 5 Treatment with BMS (PO BID) protects from wasting and colitis in two SCID mouse models. Treatment with BMS (PO BID) protects from wasting and colitis in two SCID mouse models. A blocking anti-p40 antibody was included as a comparator. In the anti-CD40 antibody–induced colitis model (n = 5 mice per group), BMS treatment was initiated immediately before challenge with anti-CD40 antibody, and (A) the mean body weight was assessed throughout the course of the disease (*P < 0.05 and **P < 0.01, one-way ANOVA with Dunnett’s posttest). (B) Histological evaluation of colons at the end of the study was scored (20× magnification), P values from one-way ANOVA with Dunnett’s posttest. (C) Representative images of hematoxylin and eosin (H&E)–stained colon sections from mice treated with vehicle, BMS (15 and 50 mg/kg), and anti-p40 antibody in the anti-CD40 antibody–induced colitis model after 6 days. (D) PK of BMS in study mice collected on the last day of the anti-CD40 antibody–induced model with the data represented as time after the morning dose. In the CD4+CD45RBhigh transfer colitis model (n = 9 mice per group), treatment with BMS was initiated immediately after transfer of cells, and (E) the mean body weight was assessed throughout the course of the disease (*P < 0.05 and **P < 0.01, one-way ANOVA with Dunnett’s posttest). (F) Histological evaluation of colons at the end of the study was scored. P values were calculated from unpaired nonparametric one-sided Mann-Whitney test. (G) Representative images of H&E-stained colon sections at day 48 from mice treated with vehicle, BMS (10 mg/kg), and anti-p40 antibody in the CD4+CD45RBhigh transfer colitis model (10× magnification). (H) PK of BMS in study mice collected on the last day of the CD4+CD45RBhigh transfer model with the data represented as time after the morning dose. The results represent means ± SEM. James R. Burke et al., Sci Transl Med 2019;11:eaaw1736 Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works

Download ppt "Fig. 5 Treatment with BMS-986165 (PO BID) protects from wasting and colitis in two SCID mouse models. Treatment with BMS-986165 (PO BID) protects from."

Similar presentations

Identification of combination treatment–responsive dysfunctional tumor-infiltrating CD8+ T cell population. Identification of combination treatment–responsive.

Identification of combination treatment–responsive dysfunctional tumor-infiltrating CD8+ T cell population. Identification of combination treatment–responsive.
Fibroblast activation in WT and NFATc2-deficient mice.

Fibroblast activation in WT and NFATc2-deficient mice.
Pathogenic potential of naïve Helicobacter-reactive CT6 cells in lymphopenic mice. Pathogenic potential of naïve Helicobacter-reactive CT6 cells in lymphopenic.

Pathogenic potential of naïve Helicobacter-reactive CT6 cells in lymphopenic mice. Pathogenic potential of naïve Helicobacter-reactive CT6 cells in lymphopenic.
IFN-γ antagonizes TGF-β in vivo.

IFN-γ antagonizes TGF-β in vivo.
FIP200 deficiency alters mitochondria activation and ROS production in T cells. FIP200 deficiency alters mitochondria activation and ROS production in.

FIP200 deficiency alters mitochondria activation and ROS production in T cells. FIP200 deficiency alters mitochondria activation and ROS production in.
IFN-γ activates the fibrinolytic system.

IFN-γ activates the fibrinolytic system.
CD8α+ DC-deficient mice are highly susceptible to Lm infection in the absence of CD169+ macrophages. CD8α+ DC-deficient mice are highly susceptible to.

CD8α+ DC-deficient mice are highly susceptible to Lm infection in the absence of CD169+ macrophages. CD8α+ DC-deficient mice are highly susceptible to.
Therapeutic effects of TIP60 allosteric modification in DSS-induced colitis. Therapeutic effects of TIP60 allosteric modification in DSS-induced colitis.

Therapeutic effects of TIP60 allosteric modification in DSS-induced colitis. Therapeutic effects of TIP60 allosteric modification in DSS-induced colitis.
Three different types of transfer functions with a codomain of [0,1].

Three different types of transfer functions with a codomain of [0,1].
Genetic FIP200 deletion impairs autophagy induction and causes T cell apoptosis. Genetic FIP200 deletion impairs autophagy induction and causes T cell.

Genetic FIP200 deletion impairs autophagy induction and causes T cell apoptosis. Genetic FIP200 deletion impairs autophagy induction and causes T cell.
Neutrophil recruitment to the colonic lamina propria depends on CD4+ T cells. Neutrophil recruitment to the colonic lamina propria depends on CD4+ T cells.

Neutrophil recruitment to the colonic lamina propria depends on CD4+ T cells. Neutrophil recruitment to the colonic lamina propria depends on CD4+ T cells.
Fig. 6 In utero injection of inflammatory cytokines or adoptive transfer of activated T cells leads to pregnancy loss. In utero injection of inflammatory.

Fig. 6 In utero injection of inflammatory cytokines or adoptive transfer of activated T cells leads to pregnancy loss. In utero injection of inflammatory.
BAP1 deficiency results in thymic atrophy and loss of thymocyte populations. BAP1 deficiency results in thymic atrophy and loss of thymocyte populations.

BAP1 deficiency results in thymic atrophy and loss of thymocyte populations. BAP1 deficiency results in thymic atrophy and loss of thymocyte populations.
IFN-γ antagonizes TGF-β in vivo.

IFN-γ antagonizes TGF-β in vivo.
Biocompatibility evaluation in vivo with a mouse subcutaneous implant

Biocompatibility evaluation in vivo with a mouse subcutaneous implant
Fig. 4 The extracellular domain of sortilin is sufficient for BDNF/TrkB signaling. The extracellular domain of sortilin is sufficient for BDNF/TrkB signaling.

Fig. 4 The extracellular domain of sortilin is sufficient for BDNF/TrkB signaling. The extracellular domain of sortilin is sufficient for BDNF/TrkB signaling.
Fig. 2 AcPGP induces IL-8 and G-CSF release from human bronchial epithelial cells. AcPGP induces IL-8 and G-CSF release from human bronchial epithelial.

Fig. 2 AcPGP induces IL-8 and G-CSF release from human bronchial epithelial cells. AcPGP induces IL-8 and G-CSF release from human bronchial epithelial.
Cell viability tests. Cell viability tests. SEM images of (A) MC3T3-E1 cells and (B) MSCs on days 1, 3, and 5 of culture. (C) Survival rates of MC3T3-E1.

Cell viability tests. Cell viability tests. SEM images of (A) MC3T3-E1 cells and (B) MSCs on days 1, 3, and 5 of culture. (C) Survival rates of MC3T3-E1.
Fig. 3 Intrarenal and RDLN lymphangiogenesis accompanied by lymphocyte expansion in the kidney, RDLN, and spleen. Intrarenal and RDLN lymphangiogenesis.

Fig. 3 Intrarenal and RDLN lymphangiogenesis accompanied by lymphocyte expansion in the kidney, RDLN, and spleen. Intrarenal and RDLN lymphangiogenesis.
Fig. 1. MSCs undergo in vivo apoptosis after infusion without affecting immunosuppression. MSCs undergo in vivo apoptosis after infusion without affecting.

Fig. 1. MSCs undergo in vivo apoptosis after infusion without affecting immunosuppression. MSCs undergo in vivo apoptosis after infusion without affecting.

Similar presentations

Ads by Google